Alnylam Pharmaceuticals Inc
Company Profile
Business description
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Contact
675 West Kendall Street
Henri A. Termeer Square
CambridgeMA02142
USAT: +1 617 551-8200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
2,500
Stocks News & Analysis
stocks
Paying more for new customers is a troubling sign for ASX share
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
stocks
Berkshire Hathaway earnings: Cash hits record $373 billion on mostly solid results across the firm
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,117.10 | 303.40 | -3.22% |
| CAC 40 | 8,195.90 | 92.06 | 1.14% |
| DAX 40 | 24,209.42 | 418.77 | 1.76% |
| Dow JONES (US) | 48,750.59 | 249.32 | 0.51% |
| FTSE 100 | 10,571.06 | 209.05 | -1.94% |
| HKSE | 25,249.48 | 1,131.54 | -4.29% |
| NASDAQ | 22,824.15 | 307.46 | 1.37% |
| Nikkei 225 | 54,245.54 | 4,507.85 | -7.67% |
| NZX 50 Index | 13,531.12 | 139.59 | -1.02% |
| S&P 500 | 6,869.78 | 53.15 | 0.78% |
| S&P/ASX 200 | 8,901.20 | 280.50 | -3.05% |
| SSE Composite Index | 4,082.47 | 40.20 | -0.98% |